Next, we sought to understand whether different levels of ATPA1, ATPA2, ATPB1, and ATPB3 mRNA expression could impact the survival of women carrying ERα-negative or ERα-positive BCs to gain insight into the possibility to use OU or possibly other CGs as an additional treatment option for tumor management. The gene discussed is ATP1B3; the disease is neoplasm.